NT-ProBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 2, 2015, Pages 205-214

  Bansal, Nisha ^a   Katz, Ronit ^a   Dalrymple, Lorien ^b   De Boer, Ian ^a   Defilippi, Christopher ^c   Kestenbaum, Bryan ^a   Park, Meyeon ^e   Sarnak, Mark ^f   Seliger, Stephen ^d   Shlipak, Michael ^e,e,g  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYSTATIN C; TROPONIN T; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CST3 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEAT STROKE; HUMAN; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; AGE; AGING; BLOOD; CLINICAL TRIAL; DISEASE COURSE; GLOMERULUS FILTRATION RATE; INCIDENCE; KIDNEY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UNITED STATES; UPREGULATION;

AGE FACTORS; AGED; AGING; BIOMARKERS; CYSTATIN C; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TROPONIN T; UNITED STATES; UP-REGULATION;

EID: 84923794931     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04910514     Document Type: Article

References (48)

1. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, Neal BC, Patel A, MacMahon SW: Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension 45: 69–74, 2005.
2. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293: 1609–1616, 2005.
3. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E: Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52: 450–459, 2008.
4. Rothenbacher D, Koenig W, Brenner H: Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 166: 2455–2460, 2006.
5. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM: Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 123: 1367–1376, 2011.
6. Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, Messeri G, Gheorghiade M, Maisel A, Zuppiroli A: The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail 15: 377–384, 2009.
7. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA: N-terminal fragment of the prohormone braintype natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297: 169–176, 2007.
8. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Münzel T, Yusuf S, Investigators HS; HOPE Study Investigators: Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 114: 201–208, 2006.
9. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, Group CS; CORONA Study Group: Plasma concentration of aminoterminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 54: 1850–1859, 2009.
10. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, Okada H, Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y: Persistently increased serum concentrations of cardiac troponin t in patientswith idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 103: 369–374, 2001.
11. Weber M, Bazzino O, Navarro Estrada JL, Fuselli JJ, Botto F, Perez de Arenaza D, Möllmann H, Nef HN, Elsässer A, Hamm CW: N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol 51: 1188–1195, 2008.
12. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358: 2107–2116, 2008.
13. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K: Localization and mechanism of secretion of B-type natriuretic peptide in comparisonwith those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195–203, 1994.
14. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA, McGuire DK: Association of troponin T detectedwith a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304: 2503–2512, 2010.
15. Mishra RK, Li Y, DeFilippi C, Fischer MJ, Yang W, Keane M, Chen J, He J, Kallem R, Horwitz EJ, Rafey M, Raj DS, Go AS, Shlipak MG; CRIC Study Investigators: Association of cardiac troponin T with left ventricular structure and function in CKD. Am J Kidney Dis 61: 701–709, 2013.
16. Mishra RK, Li Y, Ricardo AC, Yang W, Keane M, Cuevas M, Christenson R, deFilippi C, Chen J, He J, Kallem RR, Raj DS, Schelling JR, Wright J, Go AS, Shlipak MG; Chronic Renal Insufficiency Cohort Investigators: Association of N-terminal pro- B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). Am J Cardiol 111: 432–438, 2013.
17. DeFilippi CR, Fink JC, Nass CM, Chen H, Christenson R: N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 46: 35–44, 2005.
18. David S, Kümpers P, Seidler V, Biertz F, Haller H, Fliser D: Diagnostic value of N-terminal pro-B-type natriuretic peptide (NTproBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant 23: 1370–1377, 2008.
19. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR: N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 97: 1530–1534, 2006.
20. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; Creed Investigators: Cardiac natriuretic peptides are related to left ventricularmass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12: 1508–1515, 2001.
21. deFilippi CR, Seliger SL, Maynard S, Christenson RH: Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 53: 1511–1519, 2007.
22. van Kimmenade RRJ, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, Crijns HJGM, van Dieijen-Visser MP, de Leeuw PW, Pinto YM: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J AmColl Cardiol 53: 884–890, 2009.
23. Tsutamoto T, Kawahara C, Yamaji M, Nishiyama K, Fujii M, Yamamoto T, Horie M: Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. Eur J Heart Fail 11: 653–658, 2009.
24. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, Lamb EJ: B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46: 610–620, 2005.
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305, 2004.
26. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ: Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 20: 2625–2630, 2009.
27. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ: Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168: 2212–2218, 2008.
28. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, Solomon SD, Pfeffer MA: Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 58: 717–728, 2011.
29. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1: 263–276, 1991.
30. deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL: Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascularmortality in older adults. JAMA 304: 2494–2502, 2010.
31. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL: Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol 55: 441–450, 2010.
32. FDA: GFR decline as an endpoint for clinical trials in CKD. In: FDA Workshop Conference Report, Bethesda MD, FDA, 2012.
33. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Newman AB, Siscovick DS, Stevens L, Sarnak MJ: Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C. Am J Nephrol 30: 171–178, 2009.
34. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367: 20–29, 2012.
35. Erlandsen EJ, Randers E, Kristensen JH: Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 59: 1–8, 1999.
36. de Ruijter W, Westendorp RG, Macfarlane PW, Jukema JW, Assendelft WJ, Gussekloo J: The routine electrocardiogram for cardiovascular risk stratification in old age: the Leiden 85-plus study. J Am Geriatr Soc 55: 872–877, 2007.
37. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440–1463, 2005.
38. Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson RH, Hashim IA, Hoogeveen RC, Ayers CR, Sun W, McGuire DK, Ballantyne CM, de Lemos JA: Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin Tassay. J Am Coll Cardiol 63: 1441–1448, 2014.
39. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ: Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 204: 298–303, 2009.
40. Park M, Shlipak MG, Katz R, Agarwal S, Ix JH, Hsu CY, Peralta CA: Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7: 1137–1144, 2012.
41. Patel UD, Garg AX, Krumholz HM, Shlipak MG, Coca SG, Sint K, Thiessen-Philbrook H, Koyner JL, Swaminathan M, Passik CS, Parikh CR; Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) Consortium: Preoperative serum brain natriuretic peptide and risk of acute kidney injury after cardiac surgery. Circulation 125: 1347–1355, 2012.
42. Yasuda K, Kimura T, Sasaki K, Obi Y, Iio K, Yamato M, Rakugi H, Isaka Y, Hayashi T: Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease. Nephrol Dial Transplant 27: 3885–3891, 2012.
43. Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, Kollerits B, König P, von Eckardstein A; Mildto- Moderate Kidney Disease Study Group: B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 53: 1264–1272, 2007.
44. Ho JE, Hwang SJ, Wollert KC, Larson MG, Cheng S, Kempf T, Vasan RS, Januzzi JL, Wang TJ, Fox CS: Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem 59: 1613–1620, 2013.
45. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 52: 1527–1539, 2008.
46. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH: Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53: 589–596, 2009.
47. House AA: Cardiorenal syndrome: new developments in the understanding and pharmacologic management. Clin J Am Soc Nephrol 8: 1808–1815, 2013.
48. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K: Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 9: 99–111, 2013.